|
|
Endocrinology
Research Funding
(listed alphabetically by Principal Investigator or by Section faculty member involved)
2006-2008
An Open-Label Trial Evaluating the Safety and Efficacy of NOLVADEX (TOMAXIFEN-CITRATE) in the Treatment of McCune Albright Syndrome
Principal Investigator: Michael S. Kappy, MD, PhD
Source: AstraZeneca Pharmaceuticals
Amount: $10,000 per patient enrolled
Term: 2000 - ongoing
A Randomized, Double-Blind, Placebo-Controlled Trial to Assess the Safety and Efficacy of (ARIMEDEX) vs. Placebo for the Treatment of Gynecomastia of Pubertal Boys
Principal Investigator: Michael S. Kappy, MD, PhD
Source: AstraZeneca Pharmaceuticals
Amount: $6,200 per patient enrolled
Term: 2000 - ongoing
Career Development Award
Principal Investigator: Kristen Nadeau, MD
Investigator: Philip S. Zeitler, MD, PhD
Source: NCRR, NIH - K23 RR020038-01
Amount: $130,330/yr
Term: 2004 - 2009
Center for Women’s Health Research (Junior Faculty Research Development Award): Problems with Exercise in Diabetic Adolescents Intervention (PEDALING)
Principal Investigator: Kristen Nadeau, MD
Source: UCD Center for Women’s Health Research
Amount: $25,000/yr
Term: 2007 - 2008
Insulin Control of Fat Regulation and Exercise in Teens
Principal Investigator: Kristen Nadeau, MD
Source: NCRR, NIH - 5 K23 RR020038-04
Amount: $131,330
Term: 2005 - 2009
Insulin Sensitivity in Adolescents with Type 1 and Type 2 Diabetes
Principal Investigator: Kristen Nadeau, MD
Source: Juvenile Diabetes Research Foundation
Amount: $109,970/yr
Term: 2008 - 2009
Regulation of Maternal Fuel Supply and Neonatal Adiposity
Principal Investigator: Lynn Barbour, MD
Co-Investigators: Kristen Nadeau, MD, and Tracy J. Horton, PhD
Source: NIDDKD, NIH - 1R56DK078645
Amount: $163,800/yr
Term: 2007 - 2009
Search Case Control-Defining Diabetes in Youth
Principal Investigator: Richard F. Hamman, MD, DrPH
Co-Investigators: Kristen Nadeau, MD, and Philip S. Zeitler, MD, PhD
Source: NIDDKD, NIH - DK049184
Amount: $100,000/yr
Term: 2007 - 2008
Effect of Early Growth Hormone Treatment on Long-Term Growth and Skeletal Maturation in Girls with Turner Syndrome
Principal Investigator: Sharon H. Travers, MD
Source: Eli Lilly and Company
Amount: $6,398/yr
Term: 2006 - 2016
GeNeSIS: The Genetics and Neuroendocrinology of Short Stature International Study
Principal Investigator: Sharon H. Travers, MD
Source: Eli Lilly and Company
Amount: $9,200/yr
Term: 2002 - ongoing
Multicenter, Randomized, Two-Arm Study of Genotropin in Idiopathic Short Stature Patients: Comparing an Individualized, Target-Driven Treatment Regimen to Standard Dosing of Genotropin
Principal Investigator: Sharon H. Travers, MD
Source: Pfizer, Inc.
Amount: $9,032/yr
Term: 2007 - 2013
Prevention and Treatment of Type 2 Diabetes in Children and Adolescents
Principal Investigator: Philip Zeitler, MD, PhD
Co-Investigators: Kristen Nadeau, MD, Margaret Moriarty, MD, Janine Higgins, PhD, and Natalie Abramshon, PhD
Source: NIDDKD, NIH - DK61242
Amount: $469,139/yr
Term: 2002 - 2011
Defining Diabetes in Youth - Ethnic Diversity in Three Populations
Principal Investigator: Richard F. Hamman, MD, DrPH
Co-Investigator: Philip S. Zeitler, MD, PhD
Source: NIDDK, NIH - 1R01DK059184-01A2
Amount: $500,000/yr
Term: 2002 - 2006
Colorado Clinical and Translational Sciences Institute
Principal Investigator: Ronald J. Sokol, MD
Co-Directors: William W. Hay, Jr., MD, Michael G. Kahn, MD, PhD, Robert H. Eckel, MD, Mark W. Geraci, MD, Marc Moss, MD, and Andrew Kramer, MD
Medical Director of TCH CTRC: Philip S. Zeitler, MD, PhD
Source: NCRR, NIH - UL1RR025780, KL2RR025779, TL1RR025778
Amount: $76,155,655
Term: 2008 - 2013
Pediatric Clinical Translational Research Center
Principal Investigator: Richard D. Krugman, MD
Program Director: Ronald J. Sokol, MD
Associate Program Directors: William W. Hay, Jr., MD, and Philip S. Zeitler, MD, PhD
Assistant Program Director: Nancy F. Krebs, MD
Source: NCRR, NIH - MO1 RR00069
Amount: $19,434,966
Term: 2006 - 2008
Pediatric General Clinical Research Center
Principal Investigator: Richard D. Krugman, MD
Program Director: Ronald J. Sokol, MD
Associate Program Directors: William W. Hay, Jr., MD, and Philip S. Zeitler, MD, PhD
Assistant Program Director: Nancy F. Krebs, MD
Source: NCRR, NIH - M01-RR00069
Amount: $16,884,197
Term: 2001 - 2006
2005
Pediatric Clinical Translational Research Center
Principal Investigator: Richard D. Krugman, MD
Program Director: Ronald J. Sokol, MD
Associate Program Director: William W. Hay, Jr., MD
Associate Program Director: Philip S. Zeitler, MD, PhD
Assistant Program Director: Nancy F. Krebs, MD
Source: National Institutes of Health, National Center for Research Resources - M01-RR00069
Amount: $16,884,197
Term: 2001-2006
Treatment Alternatives in Pediatric Type 2 Diabetes
Principal Investigator: Philip S. Zeitler, MD, PhD
Co-Investigators: Georgeanna J. Klingensmith, MD, and Nancy F. Krebs, MD
Source: National Institutes of Health - 5U01 DK61242
Amount: $508,000/yr
Term: 2002-2009
Defining Diabetes in Youth - Ethnic Diversity in Three Populations
Principal Investigator: Richard F. Hamman, MD, DrPH
Co-Investigator: Philip S. Zeitler, MD, PhD
Source: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases - 1R01DK059184-01A2
Amount: $500,000/yr
Term: 2002-2006
Career Development Award (K23)
Principal Investigator: Kristen Nadeau, MD
Source: National Institutes of Health, National Center for Research Resources - 1 K23 RR020038-01
Amount: $131,330/yr
Term: 2004-2006
2003-2004
Defining Diabetes in Youth - Ethnic Diversity in Three Populations
Principal Investigator: Philip S. Zeitler, MD, PhD
Source: National Institutes of Health - 1 U01 DK61242-01
Amount: $500,000/yr
Term: 2002-2005
The Physiology of Growth Hormone-Releasing Hormone (GHRH) in Breast Cancer
Principal Investigator: Philip S. Zeitler, MD, PhD
Source: US Department of Defense Breast Cancer Research Program - BC990426
Amount: $74,954/yr
Term: 2000-2003
The Prevalence and Natural History of Osteopenia and Osteoporosis in Survivors of Childhood Bone Marrow Transplant
Principal Investigator: Philip S. Zeitler, MD, PhD
Source: Pediatric General Clinical Research Center
Term: 2000-2005
Treatment Alternatives in Pediatric Type 2 Diabetes
Principal Investigator: Philip S. Zeitler, MD, PhD
Co-Investigators: Georgeanna J. Klingensmith, MD, and Nancy F. Krebs, MD
Source: National Institutes of Health - 1U01 DK61242-01
Amount: $433,670/yr
Term: 2001-2009
2001-2002
An Open-Label Trial Evaluating the Safety and Efficacy of NOLVADEX (TOMAXIFEN-CITRATE) in the Treatment of McCune Albright Syndrome
Principal Investigator: Michael S. Kappy, MD, PhD
Source: AstraZeneca Pharmaceuticals
Amount: $10,000 per patient enrolled
Term: 2000-2002
A Randomized, Double-Blind Placebo-Controlled Trial to Assess the Safety and Efficacy of (ARIMEDEX) vs. Placebo for the Treatment of Gynceocmastia of Pubertal Boys
Principal Investigator: Michael S. Kappy, MD, PhD
Source: AstraZeneca Pharmaceuticals
Amount: $6,200 per patient enrolled
Term: 2000-2002
A Double-Blind, Placebo-Controlled 52-Week Study of Xenical (Orlistat) in the Weight Management of Obese Pediatric Patients
Principal Investigator: Sharon H. Travers, MD
Source: F. Hoffmann-La Roche Ltd
Amount: $ 6,326 per patient enrolled
Term: 2000-2001
The Effect of Recombinant Human Growth Hormone Treatment on the Growth of Infants and Toddlers with Turner Syndrome
Principal Investigator: Sharon H. Travers, MD
Source: Eli Lilly Pharmaceuticals
Amount: $6,326 per patient enrolled
Term: 1999-2002
Defining Diabetes in Youth - Ethnic Diversity in Three Populations
Principal Investigator: Philip S. Zeitler, MD, PhD
Source: National Institutes of Health - 1 U01 DK61242-01
Amount: $500,000/yr
Term: 2002-2005
The Hypopituitary Control and Complications Study (HypoCCS-1)
Principal Investigator: Philip S. Zeitler, MD, PhD
Source: Eli Lilly Pharmaceuticals
Amount: $1,425 per patient enrolled
Term: 1999-2002
The Physiology of Growth Hormone-Releasing Hormone (GHRH) in Breast Cancer
Principal Investigator: Philip S. Zeitler, MD, PhD
Source: US Department of Defense Breast Cancer Research Program - BC990426
Amount: $74,954/yr
Term: 2000-2003
The Prevalence and Natural History of Osteopenia and Osteoporosis in Survivors of Childhood Bone Marrow Transplant
Principal Investigator: Philip S. Zeitler, MD, PhD
Source: Pediatric General Clinical Research Center
Term: 2000-2005
Treatment Alternatives in Pediatric Type 2 Diabetes
Principal Investigator: Philip S. Zeitler, MD, PhD
Co-Investigators: Georgeanna J. Klingensmith, MD, and Nancy F. Krebs, MD
Source: National Institutes of Health - 1U01 DK61242-01
Amount: $433,670/yr
Term: 2001-2008
The Use of Bisphosphonates to Treat Osteoporosis in Children with Steroid-Dependent Asthma
Principal Investigator: Philip S. Zeitler, MD, PhD
Source: The Children's Hospital Research Institute
Amount: $30,000
Term: 1999-2001
The Use of Pamidronate to Treat Osteoporosis in Children with Steroid-Dependent Asthma
Principal Investigator: Philip S. Zeitler, MD, PhD
Source: Novartis Pharmaceuticals Corporation
Amount: $20,000
Term: 2000-2001
1999-2000
An Open-Label Trial Evaluating the Safety and Efficacy of NOLVADEX (TOMAXIFEN-CITRATE) in the Treatment of McCune Albright Syndrome
Principal Investigator: Michael S. Kappy, MD, PhD
Source: AstraZeneca Pharmaceuticals
Amount: $10,000 per patient enrolled
Term: 2000-ongoing
A Randomized, Double-Blind Placebo-Controlled Trial to Assess the Safety and Efficacy of (ARIMEDEX) vs. Placebo for the Treatment of Gynceocmastia of Pubertal Boys
Principal Investigator: Michael S. Kappy, MD, PhD
Source: AstraZeneca Pharmaceuticals
Amount: $6,200 per patient enrolled
Term: 2000-ongoing
The Effect of Recombinant Human Growth Hormone Treatment on the Growth of Infants and Toddlers with Turner's Syndrome
Principal Investigator: Sharon H. Travers, MD
Source: Eli Lilly Pharmaceuticals
Amount: $6,326 per patient enrolled
Term: 1999-2001
A Double-Blind, Placebo-Controlled 52 Week Study of Xenical (orlistat) in the Weight Management of Obese Pediatric Patients
Principal Investigator: Sharon H. Travers, MD
Source: F. Hoffmann-La Roche
Amount: $ 6,326 per patient enrolled
Term: 2000-2001
The Use of Bisphosphonates to Treat Osteoporosis in Children with Steroid Dependent Asthma
Principal Investigator: Philip Zeitler, MD, PhD
Source: Children's Hospital Research Institute
Amount: $30,000
Term: 1999-2001
The Use of Pamidronate to Treat Osteoporosis in Children with Steroid Dependent Asthma
Principal Investigator: Philip Zeitler, MD, PhD
Source: Novartis Pharmaceuticals
Amount: $20,000
Term: 2000-2001
The Physiology of Growth Hormone-Releasing Hormone (GHRH) in Breast Cancer
Principal Investigator: Philip Zeitler, MD, PhD
Source: Department of Defense Breast Cancer Research Program
Amount: $74,954/yr
Term: 2000-2003
Growth Impairment and Adrenal Suppression in Children Receiving High-Dose Inhaled Steroid Therapy for Asthma
Principal Investigator: Philip Zeitler, MD, PhD
Source: Genentech Institute for Growth
Amount: $50,000
Term: 2000-2002
The Hypopituitary Control and Complications Study (HypoCCS)
Principal Investigator: Philip Zeitler, MD, PhD
Source: Eli Lilly Pharmaceuticals
Amount: $1,425 per patient enrolled
Term: 1999-ongoing
The Hypopituitary Control and Complications Study (HypoCCS-1)
Principal Investigator: Philip Zeitler, MD, PhD
Source: Eli Lilly Pharmaceuticals
Amount: $1,425 per patient enrolled
Term: 1999-ongoing
|
|
